Summary: The board of directors of Pharmexa has today issued warrants to
selected employees as authorised by the annual general meeting. The issued
warrants allow for subscription of 1,600,000 shares of nominally DKK 5 each in
Pharmexa by cash payment, equal to a nominal value of DKK 8,000,000. The
exercise price will be DKK 3.91 per share of nominally DKK 5 with an additional
10% p.a. per running year from the allocation date and until the exercise date.
However, the exercise price will never be less than DKK 5 per share of
nominally DKK 5.
The board of directors' decision to issue warrants is in accordance with the
authorisation provided for in article 4.7 of the Company's articles of
association following which warrants may be issued without any pre-emption
right for the present shareholders of the Company.
The exercise price will be DKK 3.91 per share of nominally DKK 5% with an
additional 10% p.a. per running year from the allocation date and until the
exercise date. However, the exercise price will never be less than DKK 5 per
share of nominally DKK 5.
The warrants may be exercised wholly or partly in each of the windows that
occur in the subscription period from January 1, 2011 until December 31, 2012.
A window is defined as a period of two weeks after the company's announcement
of its annual or quarterly reports.
The market value of these warrants is calculated to DKK 1.56 per warrant. The
market value of issued warrants is calculated as of March 12, 2008 based on
Black-Scholes formula for valuation of warrants. The calculations have been
based on the assumptions of no dividend, a volatility of 50%, a risk free
interest rate of 4,26% pro anno, expected warrant span of 4.8 years and an
average share price as of March 12 of DKK 3.9 per share.
Hørsholm, March 13, 2008
Jakob Schmidt
Chief Executive Officer
Additional information:
Jakob Schmidt, CEO, tel +45 4516 2525
Claude Mikkelsen, Vice President, Corporate Affairs and Communication, tel +45
4516 2525 or +45 4060 2558
For the editors: Pharmexa A/S is a leading company in the field of active
immunotherapy and vaccines for the treatment of cancer, serious chronic and
infectious diseases. Pharmexa's proprietary technology platforms are broadly
applicable, allowing the company to address critical targets in cancer and
chronic diseases, as well as serious infectious diseases such as HIV,
influenza, hepatitis and malaria. Its leading programs are GV1001, a peptide
vaccine that has entered phase III trials in pancreatic cancer and phase II
trials in liver cancer, and HIV and hepatitis vaccines in phase I/II.
Collaborative agreements include H. Lundbeck, GENimmune, IDM Pharma, Bavarian
Nordic and Ichor Medical Systems. With operations in Denmark, Norway and USA,
Pharmexa employs approximately 80 employees and is listed on the Copenhagen
Stock Exchange under the trading symbol PHARMX.
